JAK2 and leukemia: The imatinib+ISRIB drug combination also attenuated IFNγ signaling and the immune response, which in leukemia can additionally mediate activation of the JAK2/STAT5 pathway and the inflammatory response (Fig. 5A, marked in blue; for all clusters, see Fig. S5B).